Colorectal Cancer

Niederhuber JE, Ensminger WD : Treatment of Metastatic cancer to the liver. In : Cancer : Principles and Practice of Oncology. Devita VT, Hellman S, Rosenberg SA eds, Pliladelphia, JB Lippincott, 1933, 2201-2224.

Pass HI : Treatment of metastatic cancer to the lung. In :Cancer : Principles and Practice of Oncology. Devita VT, Hellman S, Rosenberg SA, eds, Paila-delphia, JB Lippincott, 1993, 2186-2220.

Duttenhaver JR, Hoskins RB, et al : Adjuvant postoperative radiation theray in the managent of adenocarcinoma of the colon Cancer 1986 ; 57 57 : 955-963.

Willet CG, Tepper JE, et al : Indications for adjuvant radiotherapy in extrapelvie colon carcinoma. Oncology 1986 ; 3 : 25-33.

Laurie FA, Moertel CG, et al : Surgical adjuvant of large bowel carcinoma : An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989 ; 7 : 1447-1456.

Moertel CG, Flemming TR, et al : Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990 : 322 : 352-358.

Taylor I, Machin D, et al : A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985 ; 72 : 359-362.

Wolmark N, Rockette H, et al : Adjuvant therapy of Dukes' A, B and Cadenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion : Preliminary results of a National Surgical Adjuvant Breast and Bowel Project protocol C-02. J Clin Oncol 1990 ; 8 : 1466-1475.

Cohen AM, Minsky BD, Friedman MA : Rectal cancer. In : Cancer : Principles and Practice of Oncology. De Vita VT, Hellman S, Rosenberg SA, eds, Philadelphia, JB Lippincott, 1993, 978-1005.

Papillon J : Present status of radiation therapy management of rectal cancer. Radiother Oncol 1990 ; 17 : 275-283, 1990.

Willet CG, Tepper JE, et al : Patterns of failure failure following local and local excision and local excision and postoperative radiation therapy for invasive recial adenocarcinoma. J Clin Oncol 1989 ; 7 : 1003-1008.

Minsky BD, Cohen AM, et al : Phase III trial of pre-oprative radiative radiation therapy and coloanal anastomosis in distal invasive resectable rectal cancer. Int Radiat Oncol Biol Phys 1992 ; 23 : 387-392.

Douglas HO, Moertel CG, et al : Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986 ; 315 : 1294-1295.

Fisher B, Wolmark N, et al : Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer : Results from NSABP protocol R-01. JNCI 1988 ; 80 : 20-29.

Krook JE, Moertel CG, et al : Effective adjuvant surgical therapy for high-risk rectal carcinoma N Engl J Med 1991 ; 324 : 709-715.

Willet CG, Shellito PC, et al : Intraoperative electron beam radiation therapy for primary locally advanced rectal and rectosigmoid carcinoma. J Clin Oncol 1991 ; 9 : 843-849.

Willet CG, shellito PC, et al : Intraoperative electron beam radiation therapy for recurrent locally advanced rectal or rectosigmoid carcinoma Cancer 1901 - Short on tim Ask Al Assistant

Boice ID Jr, Greene MN, Ki.llen Jy, et al. Leukemia and preleukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 1983 ; 309 : 1079-1083.

Moertel CG, Schutt AJ, Hahn RG, et al. Therapy of advanced colorectal cancer with a com bination of 5-fluorouracil, methyl 3-cis (2-chlorethy)-chlorethyl-1 nitrosourea and vincristine. INCI 1975 ; 54 : 69-71.

Moertel CG. Chemotherapy of gastrointestinal cancer. N Engl J med 1978 ; 299 : 1049-1052.

Posey L, Morgan LR. Methyl CCNU versus methey CNU and 5-fluorouracil in arcinoma of large bowel. Carcinoma of the large bowel. Cancer Treat Rep 1977 ; 61 : 1453-1458.

Kemeny N, Yagoda A, Braun J. Metastatic colorectal carcinoma : A prospective trial of methyI CCNU, 5-fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep). Cancer 1983 ; 51 : 20-25.

Ahlgren JD. Chemotherapy. In : Wanebo HJ, ed. Colorectal Cancer. St. Louis, Mosby. 1993 ; 523-539.

Rougier P, Hay JM, Olivier IM, Olivier JM, et al. A controlled multicentric trial of intrahepatic artery chemotherapy vs. standard palliative treatment fur colorectal liver metastases. Porc Am Soc Clin Oncol 1990 ; 9 : 104.

Hohn DC, Stagg RJ. Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver : The Northern California Oncology Group Trial. J Clin Oncol 1989 ; 7 : 1646-1654.

Chang AF, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional vs systemic continuous 5-FU chemotherapy in the treatment of colorectal melastases. Ann Surg 1987 ; 206 : 685-693.

Martin JK, O' Connell MJ, Wicand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990 ; 125 : 1022-1027.

Lokich JJ, Ahigren JD, Gullo JJ, et al. A randoinized comparison of continuous infusion fluorouracil schedule in metastatic colorectal carcinoma : a Mid-Atlantic Program Study. J Clin Oncol 1989 ; 7 : 45-432.

Wade JL, Herbst S, Greenburg A. Prolonged venous infusion (PVI) of 5-fluorouracil (5-FU) for metastalic colon cancer. Proc Am Soc Clin Oncol 1986 ; 5 : 88.

Hansen E. Qvebbeman R, Ausman R, etal. Continuous 5-fluouracil (5-FU). infusion in colorectal cancer : Update of the MCW experience. Proc Am Soc Clin Oncol 1987 ; 6 : 80.

Molina R, Fabian C, Slavix M, et al. Reversal of palmar-plantar erythrodysesthesia (PPE) by B6 without loss of response in colon cancer patients recciving 200 mg/m2/d continuous 5-FU (Abstract) Proc Am Soc Clin Oncol 1987 ; 6 : 74.

Belt RJ, Davidner MI.,Myron MC, et al. Continuous low dose 5-fluorouracil (5-FU) for adenocarcinoma : Confirmation of activity. Proc Am Soc Clin Oncol 1985 ; 4 : 90.

Leichman L, Seichman CG, Kinzie J, et al. Long ter low dose 5-fluorouracil (5-FU) in advanced measurable colon cancer : No correlation beetween toxicity and efficacy. Proc Am Soc Clin Oncol 1985 ; 4 : 86.

Benedetto P. Davila E, Solomaon J. Chronic continous systemic infusion of 5-fluorouracil (5-FU) for metastatic in treatment of metastatic colo- rectal carcinoma (CCA). Proc Am Soc Clin Oncal 1984 ; 3 : 142.

Lonn U, Lonn S. Interaction of 5-fluorouracil and DNA of human colon adenocarcinoma. Cancer Res. 1988 ; 44 : 3414-3418.

Sawyer R, Stolfi RL, Martin DS, et al. Incorporation of 5-fluorouracil into murine bone marrow DNA in vivo. Cancer Res. 1984 ; 44 :1947-1851.

Cory JG, Breland JC, Carter GL, et al. Efts of 5-Iluorouracil in RNA metabolism in Novikoff hepatoma cells.

Spiegciman S, Sawyer R, Navak R, et al. Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc Natl Acad Sci USA. 1980 ; 77 : 4966-4970.

Gomez J, Pazdur R Biochemical modulation of 5-fluorouracil by folinic acid : I by folinic acid : a pharmacologically designed approach to drug development. Cancer Bull 1991 ; 43(3) ; (3) : 259-264.

Waxman S, Buckner H. The enhancement of S-fluorouracil antimetabolic activity by leucovorin, menadione, and alpha-tocopherol. Eur J Cancer Clin Oncol. 1982 ; 18 : 685-692.

Keyomarsi K, Moran RG, Folinic acid augmentation on munrine and human lecukemic cells. Cancer Res. 1986 ; 46 : 529-5235.

Mini E, Moroson BA, Bertino JR, et al. Cytotoxicity of fluorouridine and 5-fluorouracil in human T-lymphoblast leukemia cells : enhancement by leucovorin. Cancer Treat Rep. 1987 ; 71 : 381-389.

Spears CP, Gustavsson BG, Mitchell MS, et al Thymidylate synthase inhibition in malignant tumors and normal liver of patients given bolus intravenous 5-fluorouracil. Cancer Res. 1984 ; 44 : 4144-4150.

Huennekens FM, Duffy Th, vitols KS. Folic acid and its disruption by pharmacologic agents. NCI Monograph. 1987 ; 5 : 1-8.

Petrelli N, Herrera L, Rustum y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil versus 5-7luorouracil and highdose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carci- noma. J Clin Oncol. 1987 ; 5 : 1559-1565.

Petrelli N, douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma : a prospective randomized phase III trial. J Clin Oncol. 1989 ; 7 : 1419-1426.

Nobile MT, Vidili MG, Sobrero A, et al. 5-flurouracil alone or combined with high dose folin i acid in advanced colorectal cancer patients : a randomized trial.Proc Am Soc Clin Oncol. 1988 ; 7 : 97. Abatract.

Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal carcinomal with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotre- xate, fluorouracil, leucovorin : a randornized trial of the Northem California Oncology Group. I Clin Oncol. 1987 ; 7 : 1427-1436.

Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988 ; 6 : 469-475.

Doroshow JH, Bertrand M, Multhauf P, et al. Porspective randomized trial comparing 5-FU versus 5-FU and high dose folinic acid for treatment of advanced colorectal cancer. Proc M Soc Clin Oncol. 1987 ; 6 : 96. Abstract.

Costanzo FD, Barolucci R, Sofra M, et al. 5- fluorouracil alone versus high dose folinic acid and 5-FLJ in advanced colorectal cancer : a rando- mized trial of the Italian Oncology Group for Clinical Research. Proc AM Soc Clin Oncol. 1989 ; 8 : 106. Abtract.

Labianca R, Pancera G, Beretta G, et al. A randomized study of intravenous fluorouracil plus or minus folinic acid in advaced metastatic colorctal carcinoma. Proc Am Soc Clin Oncol. 1989 ; 8 : 118.

Poon MA, O'connell MF, Moertel CG, et al. Biochemical modulation of fluorouracil : evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989 ; 7 : 1407.

Elias L, Crissman H : Interferon effects upon the adenocarcinama 38 and HI, 60 cell lines : Antiproli- ferative responses and synergistic interaction with halogenated pyrimidine antimetabolites. Cancer Res 1988 ; 48 : 4868-50 : 4873.

Wadler S, Wersto R, Weinberg V, et al. Interaction of fluorouracil and inferferon and interferon in buman colon cancer cell lines : Cytotoxic and cytokinetic effects Cancer Res 1990 ; 50 : 5735-5739.

Elias L, Sandoval JM. Interferon efects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1989 ; 163 : 867-874.

Chu E, Zinn S, Boarman D, et al. The interaction of gamma interferon and 5-fluorouracilin the H 630 human colon carcinoma cell line. Cancer Res 1990 ; 50 : 5834-5840.

Grem JL, McAtee N, Murphy RJ, et al. A pilot study of interferon alfa-2a incombination with fluorouracil plus high dose leucovorin in metastatic gastrointesinal carcinoma. J Clin Oncol 1991; 9 : 1811-1820.

Wadler S, Wiemik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Sem in Oncol 1990 ; 17 (Suppl I) : 16-21.

Pazdur R. Ajani JA, Patt YZ, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990 ; 8 : 2027-2031.

Kemeny N, Younes A, Sciter K, et al. Interferon alfa-2a and 5-fluorouracil for advanced colorectal carcinoma : Assessment of activity and toxicity. Cancer 1990 ; 66 : 2470-2475.

Wadler S. Lembersky B, Atkins M, et al. Phase II of fluorouracil and recombinant interferferon alfa-2a in patients with advanced colorectal carcinoma : An Eastem Cooperative Oncology Group Study. J Clin Oncol 1991 ; 9 : 1806-1810.

Huberman M, McClay E, Atkins M, et al. Phase II trial of 5-fluorouracil and recombinant interferon alpha-2a in advanced colorectal cancer. Proc Am Soc Clin Oncol 1991 ; 10 : 153.

Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT Phase II studies. Cancer Chemother Pharmacol 1988 ; 22 : 333-338

Suemasu K, Nomoto C, Higashi Y. concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT. Jpn I Cancer Chemother 1982 ; 9 : 667-671.

Tsujimoto T, Sakai S, Murata M, Sasaki R. Concentrations of 5-FU in the tissue and serum of the patients with head and neck malignant tumors by preoperative administration of UFT. Jpn J Cancer Chemother 1983 ; 10 : 78-83.

Murakami M, Ota K. Clinical results 'of UFT therapy for malignant tumors under cooperative study (phase II study). Jpn J Cancer Chemother 1980 ; 7 : 1579-1586. 304 : Murakami M, Ota K. Clinical results of UFT therapy for malignant tumors under cooperative study (phase II study). Jpn J cancer chemother 1980 ; 7 : 1579-1586.

Watanabe H, yamamoto S, Naito T. Clinical results of oral UFT therapy under cooperative study. Jpn J Cancer Chemother 1980-1596.

Shirakawa S, Uchara N, Kita K, Sasu K. Clinical trial on the effect of UFT. Jpn J Cancer Chemother 1981 ; 8 : 101-105.

Jaiyessimi I, Pazdur R, Rhodes V, et al. Phase I study of Tegaftur plus uracil coadministered with oral leucovorin. Proc Am Soc Clin Oncol 1994 ; 13 ; 164 (Abstract No 451)

Pazdur R, Rhodes V, Lassere B, et al. UFT plus leucovorin : a potentially effective oral regimen in colorectal carcinoma. Proc Am Soc Clin Oncol 1994 ; 13 : 201 (Abstract No 590)

Grem JI., King SA, O' Dwyer PJ, et al. Biochemistry and clinical activity of N-(phosponacetyl)-L aspartate : A review. Cancer Res 1988 ; 48 : 4441-4454.

Kensler T, Erlichman C, Jayaran HN, et al. Peripheral leucocytes as indicators of the enzymatic effects of N-(phosphoacetyl)-L-aspartic acid (PALA) on humon L-aspartate transcarbamoylase (ATCase) activity. Cancer Treat Rep 1980 ; 64 : 967.

Ardaland B, Singh G, Siberman H. A randomized phase I and II study of short-term infusion of high dose fluorouracil with or without N-(phosphohacetyl) -L-aspartic acid in patients with advanced pancreatic and colorecal cancers. J Clin Oncol 1988 ; 6 : 1053-1058.

Mackintosh J, Coates a, Swanson C et at al : Chemotherapy of advanced colorectal cancer : a randomized trial of sequential methotrexate and 5-fluorouracil, Am J Clin Oncol 1987 ; 10 : 210.

Nordic Gastrointestinal Tumor Adjuvant study Group : Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma : a randomized trial. J Clin Oncol 1989 ; 7 : 1437.

Machiavelli M, Loone B, Romero A et al : Advanced colorectal carcinoma (CRCC) : a prospective randomized trial of sequential methotrexate (MTX)- 5-fluorouracil (5-FU) vs. 5-FU alone. Proc Am Soc Cline Oncol 1992 ; 9 : 102.

March JC, Bertino J, Katz KH et al : The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Cin Oncol 1991 ; 9 : 371.

Kao AK, Muggia FM, Dubin N et al : Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer. Cancer Treat Rep 68 : 1383, 1984.

Lokich JJ, Pirman SW, Skarin AT : Combined 5-fluorouracil and hydroxyurea therapy for gastroin testinal cancer, Oncology 1975 ; 32 : 34.

Lokich J, Anderson N, Bern M et al : Dual modulation of 5-fluorouracil using leucovorin and hydroxy urea : a phase I trial, Cancermain 1991 ; 68 : 744.

Grem JL, , fisher PH : Alteration of fluorourcil metabolism in human colon cancer cells by dipyrida- mole with a selective increase in fluorodeoxyuridine monophosphate levels, Cancer Res 1986 ; 46 : 6191.

Grem JL, Fisher PH : Alteration of fluorourail metabolism in human colon cancer cells by dipyrida- mole with a selective increase in fluorodeoxyuridine nonophosphate levels. Cancer Res 1986 ; 46 : 7206.

Remick SC, Grem JL, Fischer PH et al : Phase I rial of 5-fluorouracil and dipyridamole administered by 72-hour concurrent continuous infusion, Cancer Res 1990 ; 50 : 2667.

Budd CT, Jayaraj, Grabowski Det al. Phase I trial of dipyridamole with 5-fluorouracil and fluorouracil and folinic acid. Cancer Res. 1990 ; 50 : 7206.

Voravud N. Gene therapy of cancer. Ramathibodi Med J 1994 ; 17(2)Supp 1 : 129-173.